Enlila

About Enlila

Enlila is dedicated to targeting metabolism to extend health span and improve quality of life by supporting scientific advancements. The company focuses on translating research discoveries into therapeutic solutions to address chronic diseases associated with aging and obesity.

Products & Services

Therapeutic Solutions:Developing therapeutic approaches based on research from the Hotamışlıgil Lab at Harvard T.H. Chan School of Public Health to target mechanisms underlying chronic diseases related to aging and obesity.

Specialties

Metabolism targeting Chronic disease therapeutics Aging and obesity-related health solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Equity T: - FT: Private Equity	A: 39000000 MR: - FA: approximately USD 39 million over 10 years FAN: 39000000	D: 2025-06-16 FD: 2025-06-16	1 investors

Private Equity Latest

2025-06-16

$39.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gokhan Hotamisligil

Professor

Recent News

Enlila Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised